Skip to main content

Davita Healthcare Partners Inc(DVA-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

DaVita Statement on GLP-1 and Potential Implications on Chronic Kidney Disease

PR Newswire - Thu Oct 12, 2023

DENVER, Oct. 12, 2023 /PRNewswire/ -- DaVita issued the following statement in response to news this week from Novo Nordisk, manufacturer of Ozempic®, a glucagon-like peptide 1 (GLP-1) receptor agonist indicated for type 2 diabetes, related to its FLOW study that sought to demonstrate that Ozempic delays progression of chronic kidney disease (CKD) and lowers the risk of kidney and cardiovascular mortality. The following statement can be attributed to Dr. Jeff Giullian, chief medical officer for DaVita Inc.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe